Issue 9/2012

  • Is gene therapy finally coming into its own?

    In this issue:


    Is gene therapy finally coming into its own?

    After a balancing act that went down to the wire with regulators – and left its predecessor company bankrupt – uniQure biotherapies now looks set to become the first pharma company to gain approval for a gene therapy in Europe. the concept of ‘curing’ rare inherited diseases by altering a patient’s genome in key cells has been around for decades. But disastrous, highly-publicised failures to harness the technology in the past frightened off developers and patients alike. Now that looks set to change.

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/9/pos/1.html?sort=desc&cHash=f5f2e5fdbfbf799a701ac9c5e77ce04b

Kurszettel

Alle Kurse

TOP

  • MOLOGEN7.85 EUR5.65%
  • CYTOS0.26 CHF4.00%
  • PAION2.48 EUR2.06%

FLOP

  • 4SC1.25 EUR-2.34%
  • FORMYCON6.75 EUR-1.75%
  • VITA 343.75 EUR-1.57%

TOP

  • SANTHERA83.50 CHF27.5%
  • BB BIOTECH140.45 EUR6.3%
  • HBM86.00 CHF3.7%

FLOP

  • MOLOGEN7.85 EUR-17.4%
  • WILEX2.36 EUR-15.7%
  • MEDIGENE4.48 EUR-12.5%

TOP

  • SANTHERA83.50 CHF3695.5%
  • CO.DON2.61 EUR226.2%
  • PAION2.48 EUR185.1%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.48 EUR-67.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 27.08.2014